Abstract
Incorrectly expressed or mutated proteins associated with hematologic malignancies have been generally targeted by chemotherapy using small-molecule inhibitors or monoclonal antibodies. But the majority of these intracellular proteins are without active sites and antigens. PROTACs, proteolysis targeting chimeras, are bifunctional molecules designed to polyubiquitinate and degrade specific pathological proteins of interest (POIs) by hijacking the activity of E3-ubiquitin ligases for POI polyubiquitination and subsequent degradation by the proteasome. This strategy utilizes the ubiquitin-proteasome system for the degradation of specific proteins in the cell. In many cases, including hematologic malignancies, inducing protein degradation as a therapeutic strategy offers therapeutic benefits over classical enzyme inhibition connected with resistance to inhibitors. Limitations of small-molecule inhibitors are shown. PROTACs can polyubiquitinate and mark for degradation of “undruggable“proteins, e.g. transcription factor STAT3 and scaffold proteins. Today, this technology is used in preclinical studies in various hematologic malignancies, mainly for targeting drug-resistant bromodomain and extraterminal proteins and Bruton tyrosine kinase. Several mechanisms limiting selectivity and safety of PROTAC molecules function are also discussed.
Keywords: Proteolysis targeting chimera, ubiquitin-proteasome system, E3 ubiquitin ligase, cereblon, von hippel lindau, cellular inhibitor of apoptosis 1, leukemia, lymphoma.
Graphical Abstract
Cardiovascular & Hematological Disorders-Drug Targets
Title:Preclinical Studies of PROTACs in Hematological Malignancies
Volume: 21 Issue: 1
Author(s): Ota Fuchs*Radka Bokorova
Affiliation:
- Department of Genomics, Institute of Hematology and Blood Transfusion, Prague,Czech Republic
Keywords: Proteolysis targeting chimera, ubiquitin-proteasome system, E3 ubiquitin ligase, cereblon, von hippel lindau, cellular inhibitor of apoptosis 1, leukemia, lymphoma.
Abstract: Incorrectly expressed or mutated proteins associated with hematologic malignancies have been generally targeted by chemotherapy using small-molecule inhibitors or monoclonal antibodies. But the majority of these intracellular proteins are without active sites and antigens. PROTACs, proteolysis targeting chimeras, are bifunctional molecules designed to polyubiquitinate and degrade specific pathological proteins of interest (POIs) by hijacking the activity of E3-ubiquitin ligases for POI polyubiquitination and subsequent degradation by the proteasome. This strategy utilizes the ubiquitin-proteasome system for the degradation of specific proteins in the cell. In many cases, including hematologic malignancies, inducing protein degradation as a therapeutic strategy offers therapeutic benefits over classical enzyme inhibition connected with resistance to inhibitors. Limitations of small-molecule inhibitors are shown. PROTACs can polyubiquitinate and mark for degradation of “undruggable“proteins, e.g. transcription factor STAT3 and scaffold proteins. Today, this technology is used in preclinical studies in various hematologic malignancies, mainly for targeting drug-resistant bromodomain and extraterminal proteins and Bruton tyrosine kinase. Several mechanisms limiting selectivity and safety of PROTAC molecules function are also discussed.
Export Options
About this article
Cite this article as:
Fuchs Ota *, Bokorova Radka , Preclinical Studies of PROTACs in Hematological Malignancies, Cardiovascular & Hematological Disorders-Drug Targets 2021; 21 (1) . https://dx.doi.org/10.2174/1871529X21666210308111546
DOI https://dx.doi.org/10.2174/1871529X21666210308111546 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immunomodulation Via Targeted Inhibition of Antigen Receptor Signal Transduction
Cardiovascular & Hematological Disorders-Drug Targets Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update
Current Medicinal Chemistry Nelarabine- A New Purine Analog in the Treatment of Hematologic Malignancies
Reviews on Recent Clinical Trials Biomarkers of Aging with Prognostic and Predictive Value in Non-Oncological Diseases
Current Medicinal Chemistry New Tubulin Polymerization Inhibitor Derived from Thalidomide: Implications for Anti-Myeloma Therapy
Current Medicinal Chemistry Effects of Intermittent Hypoxia and Light Aerobic Exercise on Circulating Stem Cells and Side Population, after Strenuous Eccentric Exercise in Trained Rats
Current Stem Cell Research & Therapy Protective Role of Silymarin in Early Doxorubicin-induced Cardiac Dysfunction in Children with Acute Lymphoblastic Leukemia
Infectious Disorders - Drug Targets Molecular Imaging Aided Improvement in Drug Discovery and Development
Current Biotechnology The Role of Apoptosis in Cancer Development and Treatment: Focusing on the Development and Treatment of Hematologic Malignancies
Current Pharmaceutical Design Pegylated Liposomal Doxorubicin in Salvage Chemotherapy for Multiple Myeloma Patients
Current Cancer Therapy Reviews Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site
Anti-Cancer Agents in Medicinal Chemistry MicroRNA and Cancer: Tiny Molecules with Major Implications
Current Genomics Therapeutic Immunoconjugates. Which Cytotoxic Payload: Chemotherapeutic Drug (ADC) or Radionuclide (ARC) ?
Current Cancer Therapy Reviews Purine Nucleoside Analogs as Immunosuppressive and Antineoplastic Agents: Mechanism of Action and Clinical Activity
Current Medicinal Chemistry Viral and Non-Viral Approaches for Transient Delivery of mRNA and Proteins
Current Gene Therapy Primary Sjogren’s Syndrome and the Type I Interferon System
Current Pharmaceutical Biotechnology Chronic Administration of Single Weekly Paclitaxel in Heavily Pretreated Ovarian Cancer Patients
Current Medicinal Chemistry Thromboembolic Events in Patients Treated with Anti-Angiogenic Drugs
Current Vascular Pharmacology High-Throughput Miniaturized Immunoassay for Human Interleukin-6 Using Electrochemical Sandwich-Type Enzyme Immunosensors
Current Pharmaceutical Analysis Hypocholesterolemia
Current Vascular Pharmacology